Biomarkers – News and Features

An experimental vaccine that blocks Alzheimer's-related tau protein buildup has generated a robust immune response in both mice and non-human primates, building on earlier research.

Phenotypic screening has re-emerged as a powerful strategy for identifying drugs based on their observable effects. Discover how phenotypic screening accelerates drug discovery, supports drug repurposing and enables novel therapeutic breakthroughs.

Microglia can be engineered to detect disease-specific brain changes – like amyloid plaques in Alzheimer’s disease – and deliver therapeutics exactly where needed.

A team of researchers from the University of Chicago, has identified a novel oncometabolite that accumulates in tumors and impairs immune cells’ ability to fight cancer.

Stanford Medicine researchers have created a liquid biopsy test capable of detecting cancers, molecular mechanisms of resistance to treatment and tissue injury.

A study focused on menopausal women found that estrogen-based hormone therapy improved biomarkers associated with cardiovascular health over time. In particular, the study suggests that hormone therapy may lower levels of lipoprotein.

A long-term study reveals how age, sex, genetics, and menopause influence blood biomarkers related to dementia. The study tracked neurofilament light chain proteins, glial fibrillary acidic proteins, and phosphorylated tau 181.

Research has uncovered a new way to measure changes in DNA that predict a person's age.

A study identifies beta-synuclein in blood as a potential early biomarker for Alzheimer’s disease. This protein’s levels rise 11 years before cognitive symptoms, offering promise for early diagnosis and improved treatment outcomes.

Researchers showed that approximately 80 percent of stage 3 melanoma patients who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence.